Abstracts tagged "Advanced glycation end-products (AGEs)"

Abstract Number: 2609 • 2015 ACR/ARHP Annual Meeting
The Measurement of the Skin Autofluorescence As an Indicator of Disease Progression in Rheumatoid Arthritis Patients
Slawomir Jeka¹, Pawel Zuchowski², Katarzyna Kolossa³, Marta Dura⁴ and Rafal Wojciechowski⁵, ¹Clinic of Rheumatology and Connective Tissue Diseases, University Hospital Nr 2 Dr. Jan Biziel, 85-168 Bydgoszcz, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland, Bygdoszcz, Poland, ²Independent Section of Scientific Research Coordination and Didactic Activity, University Hospital Nr 2 Dr. Jan Biziel, 85- 168 Bydgoszcz, Poland, Bygdoszcz, Poland, ³Clinic of Rheumatology and Connective Tissue Diseases, University Hospital Nr 2 Dr. Jan Biziel, 85- 168 Bydgoszcz, Poland, Bygdoszcz, Poland, ⁴Department of Radiology and Medical Imaging, University Hospital Nr 2 Dr. Jan Biziel, 85- 168 Bydgoszcz, Poland, Bygdoszcz, Poland, ⁵Clinic of Rheumatology and Connective Tissue Diseases, University Hospital Nr 2 Dr. Jan Biziel, 85-168 Bydgoszcz, Poland, Bydgoszcz, Poland
Background/Purpose: In course of rheumatoid arthritis (RA) ther is often impaired glucose metabolism, which leads to the development of diabetes mellitus (DM). One of the…
Abstract Number: 2894 • 2014 ACR/ARHP Annual Meeting
Relationship of Dermal Advanced Glycation End Products and Hand OA
Charles Eaton¹, Jeffrey Driban², Bing Lu³, Mary Roberts⁴ and Timothy E. McAlindon⁵, ¹Center for Primary Care and Prevention, Memorial Hospital of Rhode Island, Providence, RI, ²Rheumatology, Tufts Medical Center, Boston, MA, ³Rheumatology, Brigham and Women's Hospital, Foxboro, MA, ⁴Center for Primary Care and Prevention, Pawtucket, RI, ⁵Division of Rheumatology, Tufts Medical Center, Boston, MA
Background/Purpose: Hand Osteoarthritis (HOA) is characterized by the progressive destruction of articular cartilage and bony changes and is strongly and positively associated with age but…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].